Baidu
map

梅斯医学获上海创业创新大赛优胜奖

2015-10-28 蔡晓峰 MedSci原创

10月27日,由国家科技部和上海市政府主办的浦江创新论坛创业者论坛在上海举行。会上还举行了2015“创业在上海”创新创业大赛颁奖仪式,梅斯医学作为本次大赛优胜队参加了这次活动。获奖名单会上,上海市副市长周波、科技部政策法规司司长贺德方、科技部火炬高技术产业开发中心副主任杨跃承等领导发表了精彩讲话。杨跃承主任引用习近平主席的话指出:新科技革命和产业变革对全球经济结构的重塑,好比“体育比赛换到了一个新

10月27日,由国家科技部和上海市政府主办的浦江创新论坛创业者论坛在上海举行。会上还举行了2015“创业在上海”创新创业大赛颁奖仪式,梅斯医学作为本次大赛优胜队参加了这次活动。


获奖名单

会上,上海市副市长周波、科技部政策法规司司长贺德方、科技部火炬高技术产业开发中心副主任杨跃承等领导发表了精彩讲话。杨跃承主任引用习近平主席的话指出:新科技革命和产业变革对全球经济结构的重塑,好比“体育比赛换到了一个新场地”;在传统的国际发展赛场上,别人已经定好了规则,我们可以加入,但没有主动权;“如果我们能够抓住新一轮科技革命和产业变革的重大机遇,就可以在新赛场建设之初就加入其中,甚至主导一些赛场建设,从而使我们成为新的竞赛规则的重要制定者,新的竞赛场地的重要主导者”。杨跃承表示,国家将通过以下措施来迎接这个“赛场的转换”:积极发展众创空间和创业孵化体系;打造创新创业服务平台;完善创新创业政策制度;营造宽松市场环境;建立新的金融资本市场体系。

杨跃承主任讲话

梅斯医学积极响应党和国家的号召,投身医学研究方法的创新,其疾病风险数据库项目参加了2015“创业在上海”创新创业大赛,获得优胜奖,并将参加今年11月举行的全国总决赛。

梅斯医学的疾病风险数据库通过大数据方法和人工编辑,从海量的学术文献中提取有关疾病风险因素及生物标志物的信息并对数据进行结构化管理,形成专业数据库系统。疾病风险数据库能够帮助指导医学科研的进一步方向、改善某些疾病临床诊疗模式,对基础医学研究者发现相关信号通路、病理学研究者了解疾病病因、临床检验医师开发新的检验项目、临床医师预测疾病的治疗和转归情况提供了便捷,满足了科研工作者提高相关文献检索效率的需求。

据悉,目前国内尚无针对生物标志物、疾病风险等研究信息进行系统化整理,梅斯医学选择了研发疾病风险数据库,这是大数据相关技术在疾病发病和预后相关知识的系统化整理工作中的首次大规模应用。

梅斯医学(MedSci)主要从事医学知识更新和培训服务,旨在推动和加速临床医生的职业成长。梅斯医学(MedSci)是专业的临床研究与学术服务平台,降低临床医生从事临床研究的门槛,推动临床研究共享与协作,提高临床研究的便捷性和质量,发表更高质量的临床研究成果,为临床决策提供重要的证据支持与精准预测支持。

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (12)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=56864, encodeId=d2b2568645b, content=祝贺梅斯医学!!, beContent=null, objectType=article, channel=null, level=null, likeNumber=171, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=32ba1611217, createdName=medsic, createdTime=Wed Jan 13 13:03:00 CST 2016, time=2016-01-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=56865, encodeId=7b3b56865d3, content=祝贺梅斯医学!!, beContent=null, objectType=article, channel=null, level=null, likeNumber=182, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=32ba1611217, createdName=medsic, createdTime=Wed Jan 13 13:03:00 CST 2016, time=2016-01-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=56866, encodeId=705556866cf, content=赞!, beContent=null, objectType=article, channel=null, level=null, likeNumber=169, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=32ba1611217, createdName=medsic, createdTime=Wed Jan 13 13:03:00 CST 2016, time=2016-01-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=56867, encodeId=b6855686eb6, content=赞!, beContent=null, objectType=article, channel=null, level=null, likeNumber=163, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=32ba1611217, createdName=medsic, createdTime=Wed Jan 13 13:03:00 CST 2016, time=2016-01-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=56869, encodeId=7c705686983, content=good, beContent=null, objectType=article, channel=null, level=null, likeNumber=149, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=32ba1611217, createdName=medsic, createdTime=Wed Jan 13 13:03:00 CST 2016, time=2016-01-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=56870, encodeId=b4d4568e052, content=good, beContent=null, objectType=article, channel=null, level=null, likeNumber=112, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=32ba1611217, createdName=medsic, createdTime=Wed Jan 13 13:03:00 CST 2016, time=2016-01-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1276773, encodeId=4ef012e6773ef, content=<a href='/topic/show?id=bde16242956' target=_blank style='color:#2F92EE;'>#梅斯#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=74, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=62429, encryptionId=bde16242956, topicName=梅斯)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=18fc139, createdName=一闲, createdTime=Fri Oct 30 02:29:00 CST 2015, time=2015-10-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1285229, encodeId=361f1285229f0, content=<a href='/topic/show?id=77903209422' target=_blank style='color:#2F92EE;'>#创新#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=74, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=32094, encryptionId=77903209422, topicName=创新)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=512a199, createdName=lilianxiang, createdTime=Fri Oct 30 02:29:00 CST 2015, time=2015-10-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1513778, encodeId=5d5a1513e784a, content=<a href='/topic/show?id=2bc732010fd' target=_blank style='color:#2F92EE;'>#创业#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=91, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=32010, encryptionId=2bc732010fd, topicName=创业)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=631d10593130, createdName=ms9476844295372110, createdTime=Fri Oct 30 02:29:00 CST 2015, time=2015-10-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=41777, encodeId=4cfd41e772d, content=真心不错, beContent=null, objectType=article, channel=null, level=null, likeNumber=120, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=75bb1617091, createdName=Bobby7868, createdTime=Wed Oct 28 13:54:00 CST 2015, time=2015-10-28, status=1, ipAttribution=)]
    2016-01-13 medsic

    祝贺梅斯医学!!

    0

  2. [GetPortalCommentsPageByObjectIdResponse(id=56864, encodeId=d2b2568645b, content=祝贺梅斯医学!!, beContent=null, objectType=article, channel=null, level=null, likeNumber=171, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=32ba1611217, createdName=medsic, createdTime=Wed Jan 13 13:03:00 CST 2016, time=2016-01-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=56865, encodeId=7b3b56865d3, content=祝贺梅斯医学!!, beContent=null, objectType=article, channel=null, level=null, likeNumber=182, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=32ba1611217, createdName=medsic, createdTime=Wed Jan 13 13:03:00 CST 2016, time=2016-01-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=56866, encodeId=705556866cf, content=赞!, beContent=null, objectType=article, channel=null, level=null, likeNumber=169, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=32ba1611217, createdName=medsic, createdTime=Wed Jan 13 13:03:00 CST 2016, time=2016-01-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=56867, encodeId=b6855686eb6, content=赞!, beContent=null, objectType=article, channel=null, level=null, likeNumber=163, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=32ba1611217, createdName=medsic, createdTime=Wed Jan 13 13:03:00 CST 2016, time=2016-01-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=56869, encodeId=7c705686983, content=good, beContent=null, objectType=article, channel=null, level=null, likeNumber=149, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=32ba1611217, createdName=medsic, createdTime=Wed Jan 13 13:03:00 CST 2016, time=2016-01-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=56870, encodeId=b4d4568e052, content=good, beContent=null, objectType=article, channel=null, level=null, likeNumber=112, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=32ba1611217, createdName=medsic, createdTime=Wed Jan 13 13:03:00 CST 2016, time=2016-01-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1276773, encodeId=4ef012e6773ef, content=<a href='/topic/show?id=bde16242956' target=_blank style='color:#2F92EE;'>#梅斯#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=74, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=62429, encryptionId=bde16242956, topicName=梅斯)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=18fc139, createdName=一闲, createdTime=Fri Oct 30 02:29:00 CST 2015, time=2015-10-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1285229, encodeId=361f1285229f0, content=<a href='/topic/show?id=77903209422' target=_blank style='color:#2F92EE;'>#创新#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=74, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=32094, encryptionId=77903209422, topicName=创新)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=512a199, createdName=lilianxiang, createdTime=Fri Oct 30 02:29:00 CST 2015, time=2015-10-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1513778, encodeId=5d5a1513e784a, content=<a href='/topic/show?id=2bc732010fd' target=_blank style='color:#2F92EE;'>#创业#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=91, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=32010, encryptionId=2bc732010fd, topicName=创业)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=631d10593130, createdName=ms9476844295372110, createdTime=Fri Oct 30 02:29:00 CST 2015, time=2015-10-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=41777, encodeId=4cfd41e772d, content=真心不错, beContent=null, objectType=article, channel=null, level=null, likeNumber=120, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=75bb1617091, createdName=Bobby7868, createdTime=Wed Oct 28 13:54:00 CST 2015, time=2015-10-28, status=1, ipAttribution=)]
    2016-01-13 medsic

    祝贺梅斯医学!!

    0

  3. [GetPortalCommentsPageByObjectIdResponse(id=56864, encodeId=d2b2568645b, content=祝贺梅斯医学!!, beContent=null, objectType=article, channel=null, level=null, likeNumber=171, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=32ba1611217, createdName=medsic, createdTime=Wed Jan 13 13:03:00 CST 2016, time=2016-01-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=56865, encodeId=7b3b56865d3, content=祝贺梅斯医学!!, beContent=null, objectType=article, channel=null, level=null, likeNumber=182, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=32ba1611217, createdName=medsic, createdTime=Wed Jan 13 13:03:00 CST 2016, time=2016-01-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=56866, encodeId=705556866cf, content=赞!, beContent=null, objectType=article, channel=null, level=null, likeNumber=169, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=32ba1611217, createdName=medsic, createdTime=Wed Jan 13 13:03:00 CST 2016, time=2016-01-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=56867, encodeId=b6855686eb6, content=赞!, beContent=null, objectType=article, channel=null, level=null, likeNumber=163, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=32ba1611217, createdName=medsic, createdTime=Wed Jan 13 13:03:00 CST 2016, time=2016-01-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=56869, encodeId=7c705686983, content=good, beContent=null, objectType=article, channel=null, level=null, likeNumber=149, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=32ba1611217, createdName=medsic, createdTime=Wed Jan 13 13:03:00 CST 2016, time=2016-01-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=56870, encodeId=b4d4568e052, content=good, beContent=null, objectType=article, channel=null, level=null, likeNumber=112, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=32ba1611217, createdName=medsic, createdTime=Wed Jan 13 13:03:00 CST 2016, time=2016-01-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1276773, encodeId=4ef012e6773ef, content=<a href='/topic/show?id=bde16242956' target=_blank style='color:#2F92EE;'>#梅斯#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=74, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=62429, encryptionId=bde16242956, topicName=梅斯)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=18fc139, createdName=一闲, createdTime=Fri Oct 30 02:29:00 CST 2015, time=2015-10-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1285229, encodeId=361f1285229f0, content=<a href='/topic/show?id=77903209422' target=_blank style='color:#2F92EE;'>#创新#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=74, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=32094, encryptionId=77903209422, topicName=创新)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=512a199, createdName=lilianxiang, createdTime=Fri Oct 30 02:29:00 CST 2015, time=2015-10-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1513778, encodeId=5d5a1513e784a, content=<a href='/topic/show?id=2bc732010fd' target=_blank style='color:#2F92EE;'>#创业#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=91, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=32010, encryptionId=2bc732010fd, topicName=创业)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=631d10593130, createdName=ms9476844295372110, createdTime=Fri Oct 30 02:29:00 CST 2015, time=2015-10-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=41777, encodeId=4cfd41e772d, content=真心不错, beContent=null, objectType=article, channel=null, level=null, likeNumber=120, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=75bb1617091, createdName=Bobby7868, createdTime=Wed Oct 28 13:54:00 CST 2015, time=2015-10-28, status=1, ipAttribution=)]
    2016-01-13 medsic

    赞!

    0

  4. [GetPortalCommentsPageByObjectIdResponse(id=56864, encodeId=d2b2568645b, content=祝贺梅斯医学!!, beContent=null, objectType=article, channel=null, level=null, likeNumber=171, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=32ba1611217, createdName=medsic, createdTime=Wed Jan 13 13:03:00 CST 2016, time=2016-01-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=56865, encodeId=7b3b56865d3, content=祝贺梅斯医学!!, beContent=null, objectType=article, channel=null, level=null, likeNumber=182, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=32ba1611217, createdName=medsic, createdTime=Wed Jan 13 13:03:00 CST 2016, time=2016-01-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=56866, encodeId=705556866cf, content=赞!, beContent=null, objectType=article, channel=null, level=null, likeNumber=169, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=32ba1611217, createdName=medsic, createdTime=Wed Jan 13 13:03:00 CST 2016, time=2016-01-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=56867, encodeId=b6855686eb6, content=赞!, beContent=null, objectType=article, channel=null, level=null, likeNumber=163, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=32ba1611217, createdName=medsic, createdTime=Wed Jan 13 13:03:00 CST 2016, time=2016-01-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=56869, encodeId=7c705686983, content=good, beContent=null, objectType=article, channel=null, level=null, likeNumber=149, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=32ba1611217, createdName=medsic, createdTime=Wed Jan 13 13:03:00 CST 2016, time=2016-01-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=56870, encodeId=b4d4568e052, content=good, beContent=null, objectType=article, channel=null, level=null, likeNumber=112, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=32ba1611217, createdName=medsic, createdTime=Wed Jan 13 13:03:00 CST 2016, time=2016-01-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1276773, encodeId=4ef012e6773ef, content=<a href='/topic/show?id=bde16242956' target=_blank style='color:#2F92EE;'>#梅斯#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=74, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=62429, encryptionId=bde16242956, topicName=梅斯)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=18fc139, createdName=一闲, createdTime=Fri Oct 30 02:29:00 CST 2015, time=2015-10-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1285229, encodeId=361f1285229f0, content=<a href='/topic/show?id=77903209422' target=_blank style='color:#2F92EE;'>#创新#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=74, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=32094, encryptionId=77903209422, topicName=创新)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=512a199, createdName=lilianxiang, createdTime=Fri Oct 30 02:29:00 CST 2015, time=2015-10-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1513778, encodeId=5d5a1513e784a, content=<a href='/topic/show?id=2bc732010fd' target=_blank style='color:#2F92EE;'>#创业#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=91, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=32010, encryptionId=2bc732010fd, topicName=创业)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=631d10593130, createdName=ms9476844295372110, createdTime=Fri Oct 30 02:29:00 CST 2015, time=2015-10-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=41777, encodeId=4cfd41e772d, content=真心不错, beContent=null, objectType=article, channel=null, level=null, likeNumber=120, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=75bb1617091, createdName=Bobby7868, createdTime=Wed Oct 28 13:54:00 CST 2015, time=2015-10-28, status=1, ipAttribution=)]
    2016-01-13 medsic

    赞!

    0

  5. [GetPortalCommentsPageByObjectIdResponse(id=56864, encodeId=d2b2568645b, content=祝贺梅斯医学!!, beContent=null, objectType=article, channel=null, level=null, likeNumber=171, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=32ba1611217, createdName=medsic, createdTime=Wed Jan 13 13:03:00 CST 2016, time=2016-01-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=56865, encodeId=7b3b56865d3, content=祝贺梅斯医学!!, beContent=null, objectType=article, channel=null, level=null, likeNumber=182, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=32ba1611217, createdName=medsic, createdTime=Wed Jan 13 13:03:00 CST 2016, time=2016-01-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=56866, encodeId=705556866cf, content=赞!, beContent=null, objectType=article, channel=null, level=null, likeNumber=169, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=32ba1611217, createdName=medsic, createdTime=Wed Jan 13 13:03:00 CST 2016, time=2016-01-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=56867, encodeId=b6855686eb6, content=赞!, beContent=null, objectType=article, channel=null, level=null, likeNumber=163, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=32ba1611217, createdName=medsic, createdTime=Wed Jan 13 13:03:00 CST 2016, time=2016-01-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=56869, encodeId=7c705686983, content=good, beContent=null, objectType=article, channel=null, level=null, likeNumber=149, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=32ba1611217, createdName=medsic, createdTime=Wed Jan 13 13:03:00 CST 2016, time=2016-01-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=56870, encodeId=b4d4568e052, content=good, beContent=null, objectType=article, channel=null, level=null, likeNumber=112, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=32ba1611217, createdName=medsic, createdTime=Wed Jan 13 13:03:00 CST 2016, time=2016-01-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1276773, encodeId=4ef012e6773ef, content=<a href='/topic/show?id=bde16242956' target=_blank style='color:#2F92EE;'>#梅斯#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=74, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=62429, encryptionId=bde16242956, topicName=梅斯)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=18fc139, createdName=一闲, createdTime=Fri Oct 30 02:29:00 CST 2015, time=2015-10-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1285229, encodeId=361f1285229f0, content=<a href='/topic/show?id=77903209422' target=_blank style='color:#2F92EE;'>#创新#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=74, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=32094, encryptionId=77903209422, topicName=创新)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=512a199, createdName=lilianxiang, createdTime=Fri Oct 30 02:29:00 CST 2015, time=2015-10-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1513778, encodeId=5d5a1513e784a, content=<a href='/topic/show?id=2bc732010fd' target=_blank style='color:#2F92EE;'>#创业#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=91, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=32010, encryptionId=2bc732010fd, topicName=创业)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=631d10593130, createdName=ms9476844295372110, createdTime=Fri Oct 30 02:29:00 CST 2015, time=2015-10-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=41777, encodeId=4cfd41e772d, content=真心不错, beContent=null, objectType=article, channel=null, level=null, likeNumber=120, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=75bb1617091, createdName=Bobby7868, createdTime=Wed Oct 28 13:54:00 CST 2015, time=2015-10-28, status=1, ipAttribution=)]
    2016-01-13 medsic

    good

    0

  6. [GetPortalCommentsPageByObjectIdResponse(id=56864, encodeId=d2b2568645b, content=祝贺梅斯医学!!, beContent=null, objectType=article, channel=null, level=null, likeNumber=171, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=32ba1611217, createdName=medsic, createdTime=Wed Jan 13 13:03:00 CST 2016, time=2016-01-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=56865, encodeId=7b3b56865d3, content=祝贺梅斯医学!!, beContent=null, objectType=article, channel=null, level=null, likeNumber=182, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=32ba1611217, createdName=medsic, createdTime=Wed Jan 13 13:03:00 CST 2016, time=2016-01-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=56866, encodeId=705556866cf, content=赞!, beContent=null, objectType=article, channel=null, level=null, likeNumber=169, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=32ba1611217, createdName=medsic, createdTime=Wed Jan 13 13:03:00 CST 2016, time=2016-01-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=56867, encodeId=b6855686eb6, content=赞!, beContent=null, objectType=article, channel=null, level=null, likeNumber=163, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=32ba1611217, createdName=medsic, createdTime=Wed Jan 13 13:03:00 CST 2016, time=2016-01-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=56869, encodeId=7c705686983, content=good, beContent=null, objectType=article, channel=null, level=null, likeNumber=149, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=32ba1611217, createdName=medsic, createdTime=Wed Jan 13 13:03:00 CST 2016, time=2016-01-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=56870, encodeId=b4d4568e052, content=good, beContent=null, objectType=article, channel=null, level=null, likeNumber=112, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=32ba1611217, createdName=medsic, createdTime=Wed Jan 13 13:03:00 CST 2016, time=2016-01-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1276773, encodeId=4ef012e6773ef, content=<a href='/topic/show?id=bde16242956' target=_blank style='color:#2F92EE;'>#梅斯#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=74, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=62429, encryptionId=bde16242956, topicName=梅斯)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=18fc139, createdName=一闲, createdTime=Fri Oct 30 02:29:00 CST 2015, time=2015-10-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1285229, encodeId=361f1285229f0, content=<a href='/topic/show?id=77903209422' target=_blank style='color:#2F92EE;'>#创新#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=74, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=32094, encryptionId=77903209422, topicName=创新)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=512a199, createdName=lilianxiang, createdTime=Fri Oct 30 02:29:00 CST 2015, time=2015-10-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1513778, encodeId=5d5a1513e784a, content=<a href='/topic/show?id=2bc732010fd' target=_blank style='color:#2F92EE;'>#创业#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=91, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=32010, encryptionId=2bc732010fd, topicName=创业)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=631d10593130, createdName=ms9476844295372110, createdTime=Fri Oct 30 02:29:00 CST 2015, time=2015-10-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=41777, encodeId=4cfd41e772d, content=真心不错, beContent=null, objectType=article, channel=null, level=null, likeNumber=120, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=75bb1617091, createdName=Bobby7868, createdTime=Wed Oct 28 13:54:00 CST 2015, time=2015-10-28, status=1, ipAttribution=)]
    2016-01-13 medsic

    good

    0

  7. [GetPortalCommentsPageByObjectIdResponse(id=56864, encodeId=d2b2568645b, content=祝贺梅斯医学!!, beContent=null, objectType=article, channel=null, level=null, likeNumber=171, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=32ba1611217, createdName=medsic, createdTime=Wed Jan 13 13:03:00 CST 2016, time=2016-01-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=56865, encodeId=7b3b56865d3, content=祝贺梅斯医学!!, beContent=null, objectType=article, channel=null, level=null, likeNumber=182, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=32ba1611217, createdName=medsic, createdTime=Wed Jan 13 13:03:00 CST 2016, time=2016-01-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=56866, encodeId=705556866cf, content=赞!, beContent=null, objectType=article, channel=null, level=null, likeNumber=169, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=32ba1611217, createdName=medsic, createdTime=Wed Jan 13 13:03:00 CST 2016, time=2016-01-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=56867, encodeId=b6855686eb6, content=赞!, beContent=null, objectType=article, channel=null, level=null, likeNumber=163, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=32ba1611217, createdName=medsic, createdTime=Wed Jan 13 13:03:00 CST 2016, time=2016-01-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=56869, encodeId=7c705686983, content=good, beContent=null, objectType=article, channel=null, level=null, likeNumber=149, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=32ba1611217, createdName=medsic, createdTime=Wed Jan 13 13:03:00 CST 2016, time=2016-01-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=56870, encodeId=b4d4568e052, content=good, beContent=null, objectType=article, channel=null, level=null, likeNumber=112, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=32ba1611217, createdName=medsic, createdTime=Wed Jan 13 13:03:00 CST 2016, time=2016-01-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1276773, encodeId=4ef012e6773ef, content=<a href='/topic/show?id=bde16242956' target=_blank style='color:#2F92EE;'>#梅斯#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=74, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=62429, encryptionId=bde16242956, topicName=梅斯)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=18fc139, createdName=一闲, createdTime=Fri Oct 30 02:29:00 CST 2015, time=2015-10-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1285229, encodeId=361f1285229f0, content=<a href='/topic/show?id=77903209422' target=_blank style='color:#2F92EE;'>#创新#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=74, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=32094, encryptionId=77903209422, topicName=创新)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=512a199, createdName=lilianxiang, createdTime=Fri Oct 30 02:29:00 CST 2015, time=2015-10-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1513778, encodeId=5d5a1513e784a, content=<a href='/topic/show?id=2bc732010fd' target=_blank style='color:#2F92EE;'>#创业#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=91, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=32010, encryptionId=2bc732010fd, topicName=创业)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=631d10593130, createdName=ms9476844295372110, createdTime=Fri Oct 30 02:29:00 CST 2015, time=2015-10-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=41777, encodeId=4cfd41e772d, content=真心不错, beContent=null, objectType=article, channel=null, level=null, likeNumber=120, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=75bb1617091, createdName=Bobby7868, createdTime=Wed Oct 28 13:54:00 CST 2015, time=2015-10-28, status=1, ipAttribution=)]
    2015-10-30 一闲
  8. [GetPortalCommentsPageByObjectIdResponse(id=56864, encodeId=d2b2568645b, content=祝贺梅斯医学!!, beContent=null, objectType=article, channel=null, level=null, likeNumber=171, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=32ba1611217, createdName=medsic, createdTime=Wed Jan 13 13:03:00 CST 2016, time=2016-01-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=56865, encodeId=7b3b56865d3, content=祝贺梅斯医学!!, beContent=null, objectType=article, channel=null, level=null, likeNumber=182, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=32ba1611217, createdName=medsic, createdTime=Wed Jan 13 13:03:00 CST 2016, time=2016-01-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=56866, encodeId=705556866cf, content=赞!, beContent=null, objectType=article, channel=null, level=null, likeNumber=169, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=32ba1611217, createdName=medsic, createdTime=Wed Jan 13 13:03:00 CST 2016, time=2016-01-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=56867, encodeId=b6855686eb6, content=赞!, beContent=null, objectType=article, channel=null, level=null, likeNumber=163, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=32ba1611217, createdName=medsic, createdTime=Wed Jan 13 13:03:00 CST 2016, time=2016-01-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=56869, encodeId=7c705686983, content=good, beContent=null, objectType=article, channel=null, level=null, likeNumber=149, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=32ba1611217, createdName=medsic, createdTime=Wed Jan 13 13:03:00 CST 2016, time=2016-01-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=56870, encodeId=b4d4568e052, content=good, beContent=null, objectType=article, channel=null, level=null, likeNumber=112, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=32ba1611217, createdName=medsic, createdTime=Wed Jan 13 13:03:00 CST 2016, time=2016-01-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1276773, encodeId=4ef012e6773ef, content=<a href='/topic/show?id=bde16242956' target=_blank style='color:#2F92EE;'>#梅斯#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=74, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=62429, encryptionId=bde16242956, topicName=梅斯)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=18fc139, createdName=一闲, createdTime=Fri Oct 30 02:29:00 CST 2015, time=2015-10-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1285229, encodeId=361f1285229f0, content=<a href='/topic/show?id=77903209422' target=_blank style='color:#2F92EE;'>#创新#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=74, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=32094, encryptionId=77903209422, topicName=创新)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=512a199, createdName=lilianxiang, createdTime=Fri Oct 30 02:29:00 CST 2015, time=2015-10-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1513778, encodeId=5d5a1513e784a, content=<a href='/topic/show?id=2bc732010fd' target=_blank style='color:#2F92EE;'>#创业#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=91, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=32010, encryptionId=2bc732010fd, topicName=创业)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=631d10593130, createdName=ms9476844295372110, createdTime=Fri Oct 30 02:29:00 CST 2015, time=2015-10-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=41777, encodeId=4cfd41e772d, content=真心不错, beContent=null, objectType=article, channel=null, level=null, likeNumber=120, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=75bb1617091, createdName=Bobby7868, createdTime=Wed Oct 28 13:54:00 CST 2015, time=2015-10-28, status=1, ipAttribution=)]
  9. [GetPortalCommentsPageByObjectIdResponse(id=56864, encodeId=d2b2568645b, content=祝贺梅斯医学!!, beContent=null, objectType=article, channel=null, level=null, likeNumber=171, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=32ba1611217, createdName=medsic, createdTime=Wed Jan 13 13:03:00 CST 2016, time=2016-01-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=56865, encodeId=7b3b56865d3, content=祝贺梅斯医学!!, beContent=null, objectType=article, channel=null, level=null, likeNumber=182, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=32ba1611217, createdName=medsic, createdTime=Wed Jan 13 13:03:00 CST 2016, time=2016-01-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=56866, encodeId=705556866cf, content=赞!, beContent=null, objectType=article, channel=null, level=null, likeNumber=169, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=32ba1611217, createdName=medsic, createdTime=Wed Jan 13 13:03:00 CST 2016, time=2016-01-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=56867, encodeId=b6855686eb6, content=赞!, beContent=null, objectType=article, channel=null, level=null, likeNumber=163, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=32ba1611217, createdName=medsic, createdTime=Wed Jan 13 13:03:00 CST 2016, time=2016-01-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=56869, encodeId=7c705686983, content=good, beContent=null, objectType=article, channel=null, level=null, likeNumber=149, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=32ba1611217, createdName=medsic, createdTime=Wed Jan 13 13:03:00 CST 2016, time=2016-01-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=56870, encodeId=b4d4568e052, content=good, beContent=null, objectType=article, channel=null, level=null, likeNumber=112, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=32ba1611217, createdName=medsic, createdTime=Wed Jan 13 13:03:00 CST 2016, time=2016-01-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1276773, encodeId=4ef012e6773ef, content=<a href='/topic/show?id=bde16242956' target=_blank style='color:#2F92EE;'>#梅斯#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=74, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=62429, encryptionId=bde16242956, topicName=梅斯)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=18fc139, createdName=一闲, createdTime=Fri Oct 30 02:29:00 CST 2015, time=2015-10-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1285229, encodeId=361f1285229f0, content=<a href='/topic/show?id=77903209422' target=_blank style='color:#2F92EE;'>#创新#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=74, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=32094, encryptionId=77903209422, topicName=创新)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=512a199, createdName=lilianxiang, createdTime=Fri Oct 30 02:29:00 CST 2015, time=2015-10-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1513778, encodeId=5d5a1513e784a, content=<a href='/topic/show?id=2bc732010fd' target=_blank style='color:#2F92EE;'>#创业#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=91, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=32010, encryptionId=2bc732010fd, topicName=创业)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=631d10593130, createdName=ms9476844295372110, createdTime=Fri Oct 30 02:29:00 CST 2015, time=2015-10-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=41777, encodeId=4cfd41e772d, content=真心不错, beContent=null, objectType=article, channel=null, level=null, likeNumber=120, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=75bb1617091, createdName=Bobby7868, createdTime=Wed Oct 28 13:54:00 CST 2015, time=2015-10-28, status=1, ipAttribution=)]
  10. [GetPortalCommentsPageByObjectIdResponse(id=56864, encodeId=d2b2568645b, content=祝贺梅斯医学!!, beContent=null, objectType=article, channel=null, level=null, likeNumber=171, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=32ba1611217, createdName=medsic, createdTime=Wed Jan 13 13:03:00 CST 2016, time=2016-01-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=56865, encodeId=7b3b56865d3, content=祝贺梅斯医学!!, beContent=null, objectType=article, channel=null, level=null, likeNumber=182, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=32ba1611217, createdName=medsic, createdTime=Wed Jan 13 13:03:00 CST 2016, time=2016-01-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=56866, encodeId=705556866cf, content=赞!, beContent=null, objectType=article, channel=null, level=null, likeNumber=169, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=32ba1611217, createdName=medsic, createdTime=Wed Jan 13 13:03:00 CST 2016, time=2016-01-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=56867, encodeId=b6855686eb6, content=赞!, beContent=null, objectType=article, channel=null, level=null, likeNumber=163, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=32ba1611217, createdName=medsic, createdTime=Wed Jan 13 13:03:00 CST 2016, time=2016-01-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=56869, encodeId=7c705686983, content=good, beContent=null, objectType=article, channel=null, level=null, likeNumber=149, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=32ba1611217, createdName=medsic, createdTime=Wed Jan 13 13:03:00 CST 2016, time=2016-01-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=56870, encodeId=b4d4568e052, content=good, beContent=null, objectType=article, channel=null, level=null, likeNumber=112, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=32ba1611217, createdName=medsic, createdTime=Wed Jan 13 13:03:00 CST 2016, time=2016-01-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1276773, encodeId=4ef012e6773ef, content=<a href='/topic/show?id=bde16242956' target=_blank style='color:#2F92EE;'>#梅斯#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=74, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=62429, encryptionId=bde16242956, topicName=梅斯)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=18fc139, createdName=一闲, createdTime=Fri Oct 30 02:29:00 CST 2015, time=2015-10-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1285229, encodeId=361f1285229f0, content=<a href='/topic/show?id=77903209422' target=_blank style='color:#2F92EE;'>#创新#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=74, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=32094, encryptionId=77903209422, topicName=创新)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=512a199, createdName=lilianxiang, createdTime=Fri Oct 30 02:29:00 CST 2015, time=2015-10-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1513778, encodeId=5d5a1513e784a, content=<a href='/topic/show?id=2bc732010fd' target=_blank style='color:#2F92EE;'>#创业#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=91, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=32010, encryptionId=2bc732010fd, topicName=创业)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=631d10593130, createdName=ms9476844295372110, createdTime=Fri Oct 30 02:29:00 CST 2015, time=2015-10-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=41777, encodeId=4cfd41e772d, content=真心不错, beContent=null, objectType=article, channel=null, level=null, likeNumber=120, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=75bb1617091, createdName=Bobby7868, createdTime=Wed Oct 28 13:54:00 CST 2015, time=2015-10-28, status=1, ipAttribution=)]
    2015-10-28 Bobby7868

    真心不错

    0

相关资讯

在线课堂:预告:分子生物信息数据库

分子生物信息数据库种类繁多。归纳起来,大体可以分为4个大类,即基因组数据库、核酸和蛋白质一级结构序列数据库、生物大分子(主要是蛋白质)三维空间结构数据库、以上述3类数据库和文献资料为基础构建的二次数据库。来自MedSci学院的 张博士 为大家带来看关于分子生物信息数据库的课程讲解。一共4节课:课程表:分子生物信息数据库1: 基因组和分子生物信息数据库的介绍(链接)分子生物信息数据库2: 核酸序列数

我国设立前列腺癌数据库

“中国前列腺癌数据库”日前在浙江省肿瘤医院正式挂牌,这也是我国首个前列腺癌数据库。 “中国前列腺癌数据库”由吴阶平医学基金会发起组建,数据库将通过收集和管理中国前列腺癌患者的诊断、治疗和随访数据,探明中国前列腺癌的发生、发展规律,并为提升中国前列腺癌的治疗效果和临床诊疗规范化提供依据。 前列腺癌是全球第2大男性恶性肿瘤,既往在中国发生率较低。但随着人口的老龄化和生活方式的转变,中国前列腺癌的发

前列腺癌数据库将启用

通过手机终端,医生可查阅患者数据,患者可获得就诊用药等提醒服务 12月21日,吴阶平医学基金会泌尿外科学部召开新闻发布会,宣布中国前列腺癌数据库(C-CAP)将于明年1月1日启用。中国抗癌协会泌尿男性生殖系肿瘤专业委员会主任委员那彦群介绍,作为中国首个前列腺癌领域数据库,C-CAP将通过收集和管理中国前列腺癌患者的诊断、治疗和随访数据,了解中国前列腺癌发生、发展的规律,使临床诊疗更加规范;患者也

NCI公开全球很大的肿瘤基因数据库

在个体化治疗的广阔前景下,美国、英国和台湾都大力建设自己的肿瘤基因组数据库,希望通过肿瘤数据库的建设实现肿瘤患者个体化治疗,其中的变异基因分型后将成为肿瘤药物的攻击靶点,从而实现在基因组水平上对肿瘤进行靶向性治疗。 美国国家肿瘤研究所(NCI)已公开迄今为止规模最大的肿瘤相关的变异基因数据库,这些遗传信息可对肿瘤进行基因分型,其致癌基因的分子机制为靶向治疗提供依据。具有应用价值的是,研究

一些并不常见医学数据库介绍--AMED,CINAHL,ProQuest,BioOne,CPCI

AMED补充医学文献数据库AMED(Allied and Alternative Medieine)补充医学文献数据库最初是由英国图书馆医学信息中心(MIC)于2 955年研制的。MIC的功能之一是为《医学索引》(Index Medieus)和Medline提供英国医学文献的主题索引,它和一些其他数据库一起为从事医学文献检索的人员提供了很大的帮助。Medline作为医学领域一流的文献数据库,很显然

需要多少论文才能得到图灵奖?

今年3月25日,美国计算机协会(ACM)宣布,来自麻省理工学院的教授Michael Stonebraker获得2014年度“图灵奖”(第N年宣布N-1年得主),投石冲破水中天,一些与数据处理相关的微信群中喷发一股图灵奖议论热,有位教授在微信中赞叹“说数据库界一共四位传奇大师,太伟大了“,接着有几位教授提议在今年的教学PPT中,加上相关科普,激励年轻的数据库人。朋友们鼓励我来一篇非传记的、活泼一

Baidu
map
Baidu
map
Baidu
map